MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
MiNK Therapeutics (NASDAQ: INKT) has appointed Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec, former U.S. Assistant Secretary for Preparedness and Response at HHS, brings extensive expertise in biodefense and pandemic preparedness. He previously co-conceived Operation Warp Speed and directed pandemic response for HHS during COVID-19. His appointment aims to accelerate MiNK's development of allogeneic off-the-shelf invariant natural killer T (iNKT) cell therapies for infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS) and emerging threats.
MiNK Therapeutics (NASDAQ: INKT) ha nominato il Dr. Robert Kadlec nel suo Consiglio di Amministrazione. Il Dr. Kadlec, ex Sottosegretario alla Preparazione e Risposta degli Stati Uniti presso l'HHS, porta con sé una vasta esperienza nella biodefesa e nella preparazione alle pandemie. In passato ha co-concepito l'Operazione Warp Speed e diretto la risposta alla pandemia per l'HHS durante il COVID-19. La sua nomina mira ad accelerare lo sviluppo da parte di MiNK di terapie cellulari iNKT allogeniche pronte all'uso per le malattie infettive, inclusa la sindrome da distress respiratorio acuto (ARDS) indipendentemente dagli agenti patogeni e le minacce emergenti.
MiNK Therapeutics (NASDAQ: INKT) ha nombrado al Dr. Robert Kadlec en su Junta Directiva. El Dr. Kadlec, ex Subsecretario de Preparación y Respuesta de EE. UU. en el HHS, aporta una amplia experiencia en biodefensa y preparación ante pandemias. Anteriormente, co-concebió la Operación Warp Speed y dirigió la respuesta a la pandemia para el HHS durante el COVID-19. Su nombramiento tiene como objetivo acelerar el desarrollo de terapias celulares iNKT alogénicas listas para usar para enfermedades infecciosas, incluyendo el síndrome de dificultad respiratoria aguda (SDRA) independiente de patógenos y amenazas emergentes.
MiNK Therapeutics (NASDAQ: INKT)가 드. 로버트 카들렉을 이사회의 위원으로 임명했습니다. 카들렉 박사는 HHS의 전 미국 보건복지부 준비 및 대응 차관으로서 생물 방어 및 팬데믹 준비에 대한 폭넓은 전문 지식을 보유하고 있습니다. 그는 이전에 '옵스 웜 스피드'를 공동으로 구상하고 COVID-19 기간 동안 HHS의 팬데믹 대응을 지휘했습니다. 그의 임명은 MiNK의 감염병을 위한 올로겐 iNKT 세포 치료제 개발을 가속화하는 것을 목표로 하며, 병원체에 무관한 급성 호흡곤란 증후군(ARDS) 및 새롭게 나타나는 위협도 포함됩니다.
MiNK Therapeutics (NASDAQ: INKT) a nommé le Dr. Robert Kadlec au sein de son Conseil d'Administration. Le Dr. Kadlec, ancien Sous-secrétaire américain à la Préparation et à la Réponse au HHS, apporte une expertise approfondie en matière de biopréparation et de préparation aux pandémies. Il a précédemment co-conçu l'Opération Warp Speed et dirigé la réponse à la pandémie pour le HHS pendant le COVID-19. Sa nomination vise à accélérer le développement par MiNK de thérapies cellulaires iNKT allogéniques clés en main pour les maladies infectieuses, y compris le syndrome de détresse respiratoire aiguë (SDRA) agnostique aux pathogènes et les menaces émergentes.
MiNK Therapeutics (NASDAQ: INKT) hat Dr. Robert Kadlec in seinen Vorstand berufen. Dr. Kadlec, ehemaliger US-amerikanischer Staatssekretär für Vorbereitung und Reaktion im HHS, bringt umfangreiche Fachkenntnisse in Biodefense und Pandemievorbereitung mit. Er hat zuvor die Operation Warp Speed mitkonzipiert und während COVID-19 die Pandemie-Reaktion für das HHS geleitet. Seine Ernennung zielt darauf ab, die Entwicklung von allogenen, sofort einsetzbaren iNKT-Zelltherapien für Infektionskrankheiten, einschließlich pathogen-unabhängigem akutem Atemnotsyndrom (ARDS) und aufkommenden Bedrohungen, zu beschleunigen.
- Strategic appointment of Dr. Kadlec brings valuable expertise in biodefense and pandemic preparedness
- Addition of former high-ranking government official strengthens regulatory and strategic positioning
- Potential acceleration of iNKT cell platform development for infectious diseases and ARDS
- None.
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases.
Dr. Kadlec recently served as the U.S. Senate-confirmed Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) where he led interagency responses to public health emergencies and natural disasters. During the COVID-19 pandemic, Dr. Kadlec co-conceived and initiated the vaccine program known as Operation Warp Speed and directed the pandemic response on behalf of HHS. A retired career Air Force officer and physician, he earlier served senior roles in the White House, U.S. Senate, and Department of Defense. His prior roles as Deputy Staff Director for the Senate Select Committee on Intelligence and his work on the Pandemic and All-Hazards Preparedness Act and PREVENT Pandemics Act exemplify his commitment to advancing U.S. health security. Dr. Kadlec previously directed the biodefense strategy at the White House, leading initiatives that shaped national policy for public health emergencies.
“We are thrilled to welcome Dr. Kadlec to our Board of Directors,” said Jennifer Buell, PhD, Chief Executive Officer and President of MiNK Therapeutics. “As we continue to demonstrate the transformative potential of iNKT cells as a pathogen-agnostic approach to ARDS and other immune-related conditions, Dr. Kadlec’s unparalleled expertise in public health and biodefense will be instrumental in advancing our strategic vision. His deep understanding of public health systems, coupled with his proven track record of driving innovation in medical countermeasures, makes him the ideal partner to guide MiNK through our next phase of growth. Together, we aim to harness the power of iNKT cells to address some of the most urgent challenges in global health.”
Dr. Kadlec holds a bachelor’s degree from the United States Air Force Academy, a Doctor of Medicine and a master’s degree in tropical medicine and hygiene from the Uniformed Services University of the Health Sciences, as well as a master’s degree in national security studies from Georgetown University.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
Who did MiNK Therapeutics (INKT) appoint to its Board of Directors in October 2024?
What is MiNK Therapeutics' (INKT) main therapeutic focus?
What was Dr. Kadlec's role in Operation Warp Speed?
